The identification and characterization of the C19O3 steroid metabolites of 5 alpha-androstane-3 beta,17 beta-diol produced by the canine prostate: 5 alpha-androstane-3 beta,6 alpha,17 beta-triol and 5 alpha-androstane-3 beta,7 alpha,17 beta-triol

Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS

Estrogen and its receptors (ERs) influence many biological processes in physiology and pathology in men and women. ERs are involved in the etiology and/or progression of cancers of the prostate, breast, uterus, ovary, colon, lung, stomach, and malignancies of the immune system. In estrogen-sensitive malignancies, ERβ usually is a tumor suppressor and ERα is an oncogene. ERβ regulates genes in several key pathways including tumor suppression (p53, PTEN); metabolism (PI3K); survival (Akt); proliferation pathways (p45(Skp2), cMyc, and cyclin E); cell-cycle arresting factors (p21(WAF1), cyclin-dependent kinase inhibitor 1 (CDKN1A)), p27(Kip1), and cyclin-dependent kinases (CDKs); protection from reactive oxygen species, glutathione peroxidase. Because they are activated by small molecules, ERs are excellent targets for pharmaceuticals. ERα antagonists have been used for many years in the treatment of breast cancer and more recently pharmaceutical companies have produced agonists which are very selective for ERα or ERβ. ERβ agonists are being considered for preventing progression of cancer, treatment of anxiety and depression, as anti-inflammatory agents and as agents, which prevent or reduce the severity of neurodegenerative diseases.

Early onset of puberty and early ovarian failure in CYP7B1 knockout mice

CYP7B1 is the enzyme responsible for hydroxylation and termination of the estrogenic actions of the androgen metabolite, 5alpha-androstane-3beta, 17beta-diol (3betaAdiol). 3betaAdiol is estrogenic in ERalpha or ERbeta positive cells only if they do not express CYP7B1. In this study we show that female CYP7B1(-/-) mice experience early onset of growth of the uterus and mammary glands and commence estrus cycles 2 days earlier than their wild-type littermates. Adult mammary glands and uteri appear to be under continuous estrogenic stimulation. We conclude that, by cell-specific regulation of the estrogenicity of 3betaAdiol, CYP7B1 performs two major tasks: (i) it allows 3betaAdiol to have growth inhibitory effects through ERbeta and (ii) it permits estradiol-specific activation of estrogen receptors by protection of certain cells from the estrogenic effects of 3betaAdiol. When CYP7B1 is inactivated, 3betaAdiol activates estrogen receptors indiscriminately, and the overall effect is prolonged and inappropriate exposure to estrogen.

Lycopene reduced gene expression of steroid targets and inflammatory markers in normal rat prostate

Epidemiological evidence links consumption of lycopene, the red carotenoid of tomato, to reduced prostate cancer risk. We investigated the effect of lycopene in normal prostate tissue to gain insight into the mechanisms, by which lycopene can contribute to primary prostate cancer prevention. We supplemented young rats with 200 ppm lycopene for up to 8 wk, measured the uptake into individual prostate lobes, and analyzed lycopene-induced gene regulations in dorsal and lateral lobes after 8 wk of supplementation. Lycopene accumulated in all four prostate lobes over time, with all-trans lycopene being the predominant isoform. The lateral lobe showed a significantly higher total lycopene content than the other prostate lobes. Transcriptomics analysis revealed that lycopene treatment mildly but significantly reduced gene expression of androgen-metabolizing enzymes and androgen targets. Moreover, local expression of IGF-I was decreased in the lateral lobe. Lycopene also consistently reduced transcript levels of proinflammatory cytokines, immunoglobulins, and immunoglobulin receptors in the lateral lobe. This indicates that lycopene reduced inflammatory signals in the lateral prostate lobe. In summary, we show for the first time that lycopene reduced local prostatic androgen signaling, IGF-I expression, and basal inflammatory signals in normal prostate tissue. All of these mechanisms can contribute to the epidemiologically observed prostate cancer risk reduction by lycopene.

Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate

The studies presented herein quantitated ductal branching morphogenesis in the anterior prostate (AP) of the newborn rat. Four parameters were measured: epithelial area, epithelial perimeter, node number, and form factor. Nine natural and synthetic androgens were tested for their effectiveness in inducing postnatal prostatic development using 808 newborn rat APs in 68 dose-response experiments. Based on these studies it was shown that testosterone (T) was slightly more effective than dihydrotestosterone (DHT) in supporting ductal branching morphogenesis in the developing rat AP. Furthermore, the activity of T could not be accounted for simply by conversion of T to DHT. Synthetic androgens, 7alpha-methyl-19-nortestosterone and methyltrienolone (R1881), which cannot be 5alpha-reduced to DHT, also induced extensive ductal branching and elicited responses less than those to T and not statistically different from those to DHT. This suggests that although DHT is sufficient for prostatic development, it is not necessary for postnatal ductal branching morphogenesis and growth of the prostate. 5Alpha-androstan-3alpha,17beta-diol was particularly potent in inducing ductal branching, eliciting a response greater than or comparable to those of T and DHT. Androsterone, androstanedione, 5alpha-androstan-3beta,17beta-diol and 5beta-androstan-3alpha,17beta-diol induced ductal branching, but to a lesser extent than either T or DHT. These studies challenge the assumption that DHT is essential for prostatic development, specifically during ductal branching morphogenesis of the neonatal rat prostate.

Reductive metabolism of 5 alpha-dihydrotestosterone by rat ventral and dorsolateral prostate: kinetic parameters of the enzymes

In male sex accessory organs the active androgen 5 alpha-dihydrotestosterone (DHT) is metabolized to 5 alpha-androstane-3 alpha, 17 beta-diol (3 alpha-diol) and 5 alpha-androstane-3 beta, 17 beta-diol (3 beta-diol) by the reductase activities of 3 alpha-hydroxysteroid oxidoreductase (3 alpha-HSOR; EC 1.1.1.50) and 3 beta-hydroxysteroid oxidoreductase (3 beta-HSOR; EC 1.1.1.51). After separation of radiosubstrate and products by HPLC, these enzymes activities in subcellular preparations of rat ventral and dorsolateral prostate were determined from the conversion of [3H]DHT to the radiometabolites 3 alpha-diol and 3 beta-diol and 3 beta-triols (5 alpha-androstane-3 beta, 6 alpha, 17 beta-triol plus 5 alpha-androstane-3 beta, 7 alpha, 17 beta-triol). Whereas both enzymes were found in the dorsolateral prostate, 3 beta-HSOR reductase activity was near the limit of detection in ventral prostate. Unlike the equal distribution of 3 alpha-HSOR reductase between the microsomal and cytosol fractions of the ventral prostate, both 3 alpha- and 3 beta-HSOR reductase activities of the dorsolateral prostate are mainly confined to its cytosol fraction. Km and Vmax of the 3 alpha- and 3 beta-HSOR reductases in dorsolateral prostate cytosol were 1.8 microM, 24.6 pmol.mg-1 min-1 and 25.4 microM, 45.7 pmol.mg-1 min-1, respectively. We surmise from these and earlier studies that 3 beta-HSOR reductase is the rate-limiting prostatic enzyme in the catabolic disposition of intracellular DHT.

Hydroxylation of [3H]5 alpha-androstane-3 beta,17 beta-diol by whole tissue, epithelial cells and fibroblasts from the same hyperplastic human prostate

Hydroxylations of 3 beta-hydroxy 5 alpha-dihydro C19-steroids are terminal reactions by which male accessory sex organs dispose of intracellular androgens. Cellular androgen egress is of particular interest in benign prostatic hyperplasia (BPH) where the elevated nuclear 5 alpha-dihydrotestosterone-receptor content may be implicated in the etiology of the disease. We here report substitution of hydroxyl groups at C-6 alpha, C-7 beta and predominantly at C-7 alpha of [3H]5 alpha-androstane-3 beta,17 beta-diol on incubation of 3 and 8.5 nM substrate concentrations with minced and explanted human BPH tissue. Fibroblasts isolated from the same prostatectomy specimen hydroxylated 3 nM radiosubstrate mainly at C-6 alpha, with extensive metabolism to 17-oxosteroids. Epithelial cells from the same tissue source substituted to the same extent at the three positions. Competing 3 beta-hydroxysteroid dehydrogenase exceeded hydroxylase activity only in epithelial-cell cultures. Our findings support previous evidence that prostatic epithelial and stromal cells make different contributions to androgen disposition by the 3 beta-hydroxysteroid pathway.

Metabolism of radiotestosterone to 3 beta,6 alpha- and 3 beta,7 alpha-dihydroxy 5 alpha-steroids by rat ventral, canine and human prostate in organ culture

We report here the structural assignment for the hydroxylated 5 alpha-reduced metabolites in the culture medium following incubation of radiolabelled testosterone with explants of rat ventral prostate, canine cauda epididymidis and prostate, and benign hyperplastic canine and human prostate. Explants were incubated for 21 h at 37 degrees C in surface contact with serum-free Trowell's T8 medium containing 1.7 microM or 8.5 nM substrate. After uptake determination, radiosteroid patterns in explants and media were obtained by t.l.c. The C19O3-metabolites released into the culture medium were resolved by h.p.l.c. and fractions migrating with appropriate reference compounds were crystallized to constant SA with carriers synthesized for this purpose. 5 alpha-Androstane-3 beta,6 alpha,17 beta-triol and 3 beta,6 alpha-dihydroxy-5 alpha-androstan-17-one were identified as the major C19O3-radiometabolites of rat ventral prostate. In the culture medium of canine prostate and epididymis and human prostate, 5 alpha-androstane-3 beta,7 alpha,17 beta-triol and 3 beta,7 alpha-dihydroxy 5 alpha-androstan-17-one were the principal hydroxylation products, with 6 alpha-hydroxy epimers as significant minor products of the canine prostate and epididymis and 5 alpha-androstane-3 beta,7 beta,17 beta-triol as a significant minor radiometabolite of human prostate tissue. Treatment of the castrated dog with androgen and estrogen causes an oxidative shift to striking predominance of 3 beta,7 alpha-dihydroxy 5 alpha-androstan-17-one. The 3 beta-hydroxy-5 alpha-androstane configuration of the identified C19O3-metabolites supports a pathway of prostatic and epididymal testosterone disposition which effects activation by 5 alpha-reductase and inactivation and egress by the coupled 5 alpha-3-oxosteroid reductase/3 beta-hydroxysteroid hydroxylase reactions.

Studies on the 5 alpha-androstane-3 beta,17 beta-diol-6 alpha-hydroxylase and on the 5 alpha-androstane-3 beta,17 beta-diol-7 alpha-hydroxylase in anterior hypophysis of male rats

In anterior pituitaries from male rats, it appeared that 5 alpha-androstane-3 beta,17 beta-diol was quickly metabolized into 5 alpha-androstane-3 beta,6 alpha-17 beta-triol and 5 alpha-androstane-3 beta,7 alpha,17 beta-triol by action of 6 alpha- and 7 alpha-hydroxylases. Hydroxysteroid hydroxylases were located in endoplasmic reticulum and were dependent on NADPH+. Their optimum pH was 8.0, optima temperature, 37 degrees C, and their apparent Km was 2.7 microM. Hydroxylative reactions were not reversible and not modified by gonadectomy. Hydroxylation seemed an efficient control of the pituitary level of 5 alpha-androstane-3 beta,17 beta-diol.

The role of androgen metabolism in the control of androgen action in the rat prostate

Recent results from a number of laboratories have led us to re-examine the role of 3 beta-androstanediol in the rat ventral prostate. Whereas previously 5 alpha-dihydrotestosterone and 3-beta androstanediol were thought to have distinctly separate effects on the prostate, we suggest that 3 beta-androstanediol serves only as an intermediate in the metabolism and removal of 5 alpha-dihydrotestosterone from the organ. In our view the action of androgens on the prostate are exerted exclusively through the binding of 5 alpha-dihydrotestosterone to the androgen receptor and its subsequent translocation to the nucleus. Differences in effects are related to the amount of 5 alpha-dihydrotestosterone available to the gland. 3 alpha-Hydroxysteroid dehydrogenase may play a critical role in modulating the level of 5 alpha-dihydrotestosterone available to the translocatable receptor.